Viridian Therapeutics Inc (VRDN)

NASD · Healthcare · Biotechnology · USA

Viridian Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare autoimmune diseases. The company is advancing anti-IGF-1R candidates for thyroid eye disease, FcRn inhibitors for autoimmune disorders, and a TSHR inhibitor program. Viridian conducts internal research and in-licensing, with capabilities in protein discovery, biologics manufacturing, and clinical development.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Viridian Therapeutics Inc stock.

Our verdict on VRDN

Overvalued: intrinsic value $6.31 per share, market price $30.06, margin of safety -376.1% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.31; the price of $30.06 is 376% above that value.

ETFs with the most weight in VRDN

17 more funds hold it; the full list is part of the paid plan.

More on VRDN

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than VRDN in Biotechnology

84 more in this industry show a wider margin of safety.

Is VRDN undervalued or overvalued?

VRDN is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.31; the price of $30.06 is 376% above that value.

What is the intrinsic value of VRDN?

$6.31 per share (as of the 2026-11-17 close), against a market price of $30.06. That is a margin of safety of -376.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.